Medivir completes initial Phase Ib part of HCC therapy trial

Medivir has completed the initial dose escalation part (Phase Ib) of its Phase Ib/IIa trial of fostroxacitabine bralpamide (fostrox), along with Lenvima, in hepatocellular carcinoma (HCC).